US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.24

-0.2499-0.70%

Post-market: 35.250.0137+0.04%16:10 EDT

Volume:732

Turnover:25.84K

Market Cap:16.56M

PE:- -

High:35.25

Open:35.25

Low:35.24

Close:35.49

52wk High:37.90

52wk Low:28.87

Shares:469.95K

Float Shares:469.95K

Volume Ratio:1.05

T/O Rate:0.16%

Dividend:0.41

Dividend Rate:1.16%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novartis shareholder calls for board changes, Reuters reports

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures

MT Newswires Live

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live

Market Wrap September 10: Innovation Drug Shares Dip Amid Clinical Setback, Bank Stocks Post Modest Gains

Medmix Teams with Xeris to Power Precise Delivery of New Hypothyroidism Therapy

Novartis India Hits Record High After Recent Acquisition, Distribution Deal

Tellgen's Subsidiary Device Registration Application Accepted by Regulator

Northeast Securities: Innovative Drug BD and Commercialization Deliver Consistent Wins, CXO Exceeds Projections, Traditional Segments Approach Turnaround

AI-Driven Drug Candidate From INSILICO Reaches Major Milestone As Phase 3 Trial Enrolls First Patients

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/MEDX/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.2363,"timestamp":1789761600000,"preClose":35.4862,"halted":0,"volume":732,"hourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.2363,"latestTime":"16:10 EDT","volume":6,"amount":211.4178,"timestamp":1789762204085,"change":0.0137,"changeRate":0.000389,"amplitude":0},"delay":0,"changeRate":-0.007042174140933566,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"Closed","change":-0.2499,"latestTime":"09-18 16:00:00 EDT","open":35.25,"high":35.25,"low":35.2363,"amount":25837,"amplitude":0.000386,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":35.4862,"sharesOutstanding":569946,"nav":35.46,"aum":16664285.16,"dividendRate":0.011607,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.25,"preClose":35.2363,"latestTime":"16:10 EDT","volume":6,"amount":211.4178,"timestamp":1789762204085,"change":0.0137,"changeRate":0.000389,"amplitude":0},"volumeRatio":1.04691},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.04691,"shares":469946,"dividePrice":0.409,"high":35.25,"amplitude":0.000386,"preClose":35.4862,"low":35.2363,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.2363,"eps":0,"divideRate":0.011607,"volume":732,"delay":0,"ttmEps":0,"open":35.25,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":34.9572,"twentyDayClose":37.0138,"sixtyDayClose":34.8443},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666159950","title":"Novartis shareholder calls for board changes, Reuters reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2666159950","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666159950?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047012,"startTime":"0","endTime":"0","summary":"A major Novartis (NVS) shareholder is calling for board changes following successive clinical setbacks and concerns over the company’s acquisition ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-shareholder-calls-for-board-changes-reuters-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-shareholder-calls-for-board-changes-reuters-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4578","LU0211331839.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","PPH","BK4532","LU0070302665.USD","NVS","BK4585","LU0208291251.USD","LU0320765489.SGD","MEDX","IE00B4R5TH58.HKD","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596073","title":"AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596073?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047005,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) said Thursday that atogepant for the preventive treatment of menstrual migraine in adults met its primary and all eight ranked secondary endpoints in the Phase 3 LUNA study.Atogepant dem","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0820561818.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","IE00BVYPNV92.GBP","LU0912757837.SGD","LU0511384066.AUD","IE00BSNM7G36.USD","LU1037948897.HKD","TRUH","LU2347655156.SGD","ABBV","FHLC","LU1244550221.USD","LU2125909247.SGD","LU2237443622.USD","PJP","SG9999015986.USD","LU0395794307.EUR","IXJ","LU0211328371.USD","LU0820561909.HKD","SG9999001440.SGD","LU1934455863.HKD","SG9999003800.SGD","LU1496350171.SGD","BK4139","LU0882574055.USD","LU0965509101.SGD","LU0985320562.USD","XLV","FTXH","PPH","LU1061106388.HKD","BK4534","LU0456855351.SGD","IE0004445239.USD","LU1236620834.HKD","IE00BJT1NW94.SGD","VHT","MEDX","LU2129689514.USD","LU0708994859.HKD","LU0029864427.USD","JDOC","AGNG","IYH","IE00B19Z3B42.SGD","LU1244550577.SGD","GLAM","RXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599595","title":"IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599595","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599595?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047000,"startTime":"0","endTime":"0","summary":"Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359640/0/en/imunon-enters-cooperative-research-and-development-agreement-with-national-cancer-institute-to-advance-clinical-development-of-imnn-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","GDOC","NCI","NHLD","IMNN","BK4202","BK4139","IDNA","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596813","title":"AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596813","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596813?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:00","pubTimestamp":1789045214,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide, or CGRP...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvies-atogepant-shows-positive-phase-3-results-in-menstrual-migraine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvies-atogepant-shows-positive-phase-3-results-in-menstrual-migraine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BBT3K403.USD","VHT","LU0795875086.SGD","LU0553294199.USD","BK4581","RXL","PPH","BK4139","LU2237443465.HKD","ABBV","LU0726765562.USD","LU0823416689.USD","LU0661504455.SGD","IE0000B7K699.USD","FTXH","IXJ","LU0114720955.EUR","LU0289739699.SGD","LU1057294990.SGD","IE00BN8TJ469.HKD","LU2357627491.SGD","LU1934455863.HKD","LU0256863811.USD","MEDX","LU1989772923.USD","LU1670628061.USD","IE00BSNM7G36.USD","LU0949170772.SGD","LU2237443382.USD","IYH","LU0965508806.USD","JDOC","LU0203345920.USD","BK4534","IE00B2B36J28.USD","AGNG","BK4588","BK4550","XLV","LU2089984988.USD","TRUH","IE00BFTCPJ56.SGD","LU1236620834.HKD","LU0128525929.USD","LU0859254822.USD","PJP","IE000MB6IJN5.SGD","FHLC","LU0170899867.USD","GLAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666954045","title":"Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2666954045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666954045?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739343.SGD","IE00BN8TJ469.HKD","BK4581","GLAM","LU2125909247.SGD","JDOC","RXL","LU1929549753.HKD","LU2125909593.SGD","IE000BZT7R73.USD","XLV","LU0456855351.SGD","LU0417517546.SGD","IE00BGHQF631.EUR","BK4559","FTXH","AGNG","LU1267930573.SGD","IE00BDGV0183.EUR","SG9999001440.SGD","LU0689626769.HKD","LU1291159041.SGD","LU1496350171.SGD","LU0820561909.HKD","LU2433249047.HKD","LU0158827948.USD","LU0124676726.USD","VHT","LU0289961442.SGD","ABBV","SG9999015978.USD","LU0949170772.SGD","LU0726765562.USD","MEDX","LU0545039389.USD","FHLC","LU2133065610.SGD","SG9999015986.USD","LU0170899867.USD","LU1732800096.USD","LU1989772923.USD","TRUH","IXJ","IE00BLSP4239.USD","LU1934455194.USD","IYH","PPH","LU0965508806.USD","LU1244550494.USD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666595402","title":"Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666595402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666595402?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FHLC","LU1983299246.USD","LU2237443549.SGD","LU1670628061.USD","RXL","LU2347655156.SGD","LU0965509010.AUD","LU0472753341.HKD","LU1244550221.USD","LU0432979614.USD","LU0203347892.USD","IE00B3PB1722.GBP","LU1934455194.USD","LU2089984988.USD","IE0004445239.USD","AGNG","LU1037948897.HKD","LU1093756168.USD","LU1551013425.SGD","PJP","TRUH","IE00BFTCPJ56.SGD","IXJ","LU1496350502.SGD","FTXH","MEDX","IE000BZT7R73.USD","LU0158827948.USD","XLV","IE0002141913.USD","IE00B2B36J28.USD","LU0417517546.SGD","LU2089283258.USD","PPH","LU0553294199.USD","LU1934455863.HKD","ABBV","JDOC","IE00B42XCP33.USD","LU0795875169.SGD","BK4559","LU1718418525.SGD","VHT","GLAM","LU0820561909.HKD","LU0395794307.EUR","LU1244550577.SGD","IYH","LU0122379950.USD","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666595401","title":"Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine","url":"https://stock-news.laohu8.com/highlight/detail?id=2666595401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666595401?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0203345920.USD","ABBV","BK4534","VHT","XLV","AGNG","LU0128525929.USD","JDOC","IE00BBT3K403.USD","LU0553294199.USD","LU1989772923.USD","IYH","LU2089984988.USD","LU1670628061.USD","LU0823416689.USD","LU0289739699.SGD","LU0795875086.SGD","IE0000B7K699.USD","LU0661504455.SGD","IE00B2B36J28.USD","GLAM","IE00BN8TJ469.HKD","IE00BFTCPJ56.SGD","FTXH","PPH","LU0965508806.USD","FHLC","LU0726765562.USD","LU2237443382.USD","LU2237443465.HKD","LU0170899867.USD","LU0949170772.SGD","BK4588","RXL","LU1236620834.HKD","LU0114720955.EUR","LU2357627491.SGD","BK4581","LU0859254822.USD","LU1934455863.HKD","BK4550","BK4139","IXJ","MEDX","TRUH","IE000MB6IJN5.SGD","LU0256863811.USD","LU1057294990.SGD","PJP","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666059540","title":"Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2666059540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666059540?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8RPXBH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2125909247.SGD","IE000SO60NU8.SGD","XLV","ABBV","LU1162221912.USD","AGNG","LU2468319806.SGD","LU1934455194.USD","LU2089284900.SGD","IE0000B7K699.USD","IE000BZT7R73.USD","IE0004445239.USD","LU0417517546.SGD","IE0009355771.USD","BK4534","IE00B3PB1722.GBP","IE00BBT3K403.USD","IE00B19Z3B42.SGD","SG9999001440.SGD","JDOC","LU0820561818.USD","IE0002141913.USD","LU1732800096.USD","MEDX","RXL","LU1983299246.USD","FTXH","IXJ","LU0868494708.USD","LU1496350502.SGD","VHT","IE00BVYPNW00.USD","LU2129689431.USD","LU0128525929.USD","LU0545039389.USD","LU1839511570.USD","GLAM","LU1732799900.SGD","LU1923622614.USD","PPH","LU0289739343.SGD","LU1989771016.USD","LU2237443622.USD","IYH","PJP","LU0472753341.HKD","FHLC","BK4585","TRUH","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598426","title":"Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598426","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598426?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:50","pubTimestamp":1789041051,"startTime":"0","endTime":"0","summary":"Johnson & Johnson has received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies designed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-receives-ce-marking-for-acuvue-oasys-max-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1066053197.SGD","IYH","LU2468319806.SGD","BK4581","IHE","LU0320765646.SGD","LU0234570918.USD","LU0345769631.USD","LU0787776722.HKD","LU2750360641.GBP","TRUH","PJP","GPRO","LU1280957306.USD","MEDX","IE00BDGV0183.EUR","FHLC","IE00B7SZLL34.SGD","LU0689626769.HKD","SGXZ57979304.SGD","LU1894683264.USD","LU2471134952.CNY","MAX","LU0203347892.USD","IE00BLSP4452.SGD","IE00B2B36J28.USD","IE000MB6IJN5.SGD","LU1228905037.USD","IE0000B7K699.USD","GDOC","JDOC","LU1929549753.HKD","XLV","BK4559","IE000M9KFDE8.USD","JNJ","VHT","IE00BSNM7G36.USD","SG9999002232.USD","FTXH","IE00BVYPNW00.USD","LU0345770308.USD","RXL","IXJ","IE00B3PB1722.GBP","LU0943347566.SGD","LU1032955483.USD","BK4078","BMED","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598612","title":"Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598612","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598612?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:47","pubTimestamp":1789040824,"startTime":"0","endTime":"0","summary":"Novartis  shareholder Artisan Partners called for changes to the Swiss drugmaker's board following two consecutive drug trial setbacks that sent shares tumbling, Reuters reported Thursday, citing an interview with Artisan managing director David Samra.Novartis needs stronger oversight of acquisitions, citing the $12 billion Avidity deal and the 2024 MorphoSys acquisition, which was later written down, Samra told ReutersSamra questioned the board's acquisition oversight, while Novartis reaffirmed its unchanged guidance and focus on disciplined capital allocation and shareholder returns, Reuters added.Novartis shares were up 1.7% in premarket activity.Novartis did not immediately respond to MT Newswires' request for comment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVS","BK4578","BK4588","IE0009355771.USD","BK4007","IE00BFTCPJ56.SGD","BK4585","LU0320765489.SGD","LU0211331839.USD","IE00B4R5TH58.HKD","BK4532","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0208291251.USD","PPH","MEDX","IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598631","title":"Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598631?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:45","pubTimestamp":1789040700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA26VGSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4559","LU0058720904.USD","LU2089984988.USD","LU2487616109.SGD","LU1506573853.SGD","IE00B4R5TH58.HKD","LU2129689605.HKD","LU1291159041.SGD","LU2592432038.USD","LU1032955483.USD","BK4533","IE00BJT1NW94.SGD","LU1894683264.USD","LU2750360641.GBP","LU1043141396.HKD","LU2602419157.SGD","SGXZ57979304.SGD","VHT","IE00BFXG1179.USD","LU0432979614.USD","IE00BVYPNW00.USD","IE000WAW04H5.SGD","LU1935042991.SGD","IYH","JNJ","LU0320765646.SGD","LU0345770308.USD","LU0466842654.USD","FHLC","LU1074936037.SGD","JDOC","LU1032466523.USD","FTXH","LU1057294990.SGD","LU1261432733.SGD","LU1280957306.USD","IE00BLSP4239.USD","TRUH","GDOC","PJP","BMED","IE00BBT3K403.USD","MEDX","BK4504","BK4550","LU2023250330.USD","XLV","IXJ","IHE","RXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598627","title":"CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598627","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598627?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:33","pubTimestamp":1789039980,"startTime":"0","endTime":"0","summary":"Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359400/0/en/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4168","BK4139","CMP","LENZ","NVIB","GDOC","HYLG","BK4200","UBCP","MEDX","BK4211","BK4561","IDNA","ASO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","MEDX","IBRN","PSIL","FBT","BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561456","title":"HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561456","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666561456?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:34","pubTimestamp":1789032857,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company (LLY) has an average rating of overweight and mean price target of $1,352.49, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0203201768.USD","IE00BFSS7M15.SGD","LU0672654240.SGD","SG9999015986.USD","LU2471134796.USD","SG9999017495.SGD","IE00BWXC8680.SGD","LU0354030511.USD","LU0943347566.SGD","LU0820561818.USD","LU2023250330.USD","IE0005OL40V9.USD","LU0471298777.SGD","BK4007","BK4588","LU0820561909.HKD","LU0320765059.SGD","IE0004445239.USD","LU0889565916.HKD","LU1720051017.SGD","LU2750360641.GBP","LU2750360997.AUD","XLV","LU1691799644.USD","LU0061475181.USD","TMED","VHT","SG9999014880.SGD","AGNG","LU2168564149.EUR","IE00BJLML261.HKD","LU2237443465.HKD","LU0234572021.USD","LU1979441026.SGD","LU2756315318.SGD","LU2491050071.SGD","LU2491050154.USD","SGXZ51526630.SGD","SGXZ81514606.USD","LU2023250504.SGD","LU2112291526.USD","LU2461242641.AUD","LU2237443978.SGD","LU0882574055.USD","LU0820562030.AUD","LU0096364046.USD","LU0198837287.USD","LU0466842654.USD","IE00BFSS8Q28.SGD","LU0456855351.SGD","BK4599","LU0640476718.USD","LU2111349929.HKD","LU1629891620.HKD","LU2089284900.SGD","LU2168563687.JPY","SG9999014914.USD","LU1868837300.USD","LU2106854487.HKD","LU0256863902.USD","ILDR","LU2237438978.USD","IE00BJJMRX11.SGD","PJP","LU0786609619.USD","SG9999015945.SGD","IE00B7KXQ091.USD","LU1989771016.USD","GB00BDT5M118.USD","LU0353189680.USD","LU1868836591.USD","LU1868837136.USD","LU2552382058.USD","LU1232071149.USD","LU0133085943.USD","LU0316494557.USD","LU0058720904.USD","LU2417539215.USD","LU2602419157.SGD","MEDX","LU2746668461.USD","LU1917777945.USD","LU2552382132.HKD","LU0122379950.USD","FHLC","LU0256863811.USD","PPH","SG9999014898.SGD","SGXZ57979304.SGD","IE0004445015.USD","LU1712237335.SGD","LU1974910355.USD","LU2237443895.HKD","LU0203202063.USD","LU1983299246.USD","LU0417517546.SGD","SGXZ99366536.SGD","LLII","LU0823434583.USD","BK4534","LU0432979614.USD","SG9999001176.SGD","LU0210536198.USD","LU0158827781.USD","LU1868836914.USD","IE00B2B36J28.USD","FTXH","LU2089984988.USD","LU1323610961.USD","LU1548497426.USD","HRTS","LU2552382215.SGD","LU1064131342.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU1720051108.HKD","LU1057294990.SGD","IE00B1XK9C88.USD","BK4585","LU2237443382.USD","LU2089283258.USD","LU0114720955.EUR","LU2471134952.CNY","LU1061106388.HKD","LU2471134523.USD","SGXZ31699556.SGD","ELIL","LU1623119135.USD","LU2746668974.SGD","MHIP","CANC","BK4581","SG9999015978.USD","LU2361045086.USD","LLY","LLYZ","LU0006306889.USD","LU2357305700.SGD","LU2211815571.USD","LU2168564495.EUR","LU2023251221.USD","TRUH","IYH","LU1868836757.USD","IE00BK4W5M84.HKD","LU1127390331.HKD","LU1069344957.HKD","LU0266013472.USD","LU0106261372.USD","IE00BKDWB100.SGD","THNR","LU0323591593.USD","SG9999014906.USD","JDOC","LU0094547139.USD","LU0109391861.USD","LU1551013342.USD","LU2471134879.HKD","SG9999001176.USD","IHE","OZEM","LU0353189763.USD","WDNA","LU1814569148.SGD","LU2456880835.USD","LU1093756325.SGD","LU2756315664.SGD","BK4516","LU2468319806.SGD","IE0002141913.USD","LU0689472784.USD","LU2360106947.USD","LU1267930730.SGD","LU2462157665.USD","IE00B4R5TH58.HKD","SG9999013999.USD","LU2265009873.SGD","LU2324357040.USD","SG9999018865.SGD","IE00BJJMRZ35.SGD","RXL","LU0708995401.HKD","LU0354030438.USD","LU2361044865.SGD","LU1551013425.SGD","LU1280957306.USD","LU2237443622.USD","IE0001KFT4U8.USD","LU2108987350.USD","LU2361044949.HKD","IXJ","SG9999015952.SGD","IE00BFTCPJ56.SGD","MEDI","LU2491049909.HKD","LU2168564222.USD","LU0109394709.USD","IE00BKPKM429.USD","LLYX","LU2896262040.SGD","LU2087625088.SGD","LU0320765992.SGD","LU0385154629.USD","IE00B4JS1V06.HKD","LU1145028129.USD","LU2028103732.USD","LU2236285917.USD","LU2237443549.SGD","LU0097036916.USD","LU0079474960.USD","LU0823416689.USD","IE00BK4W5L77.USD","LU0345770308.USD","LU0964807845.USD","IE0009355771.USD","IE00BJJMRY28.SGD","LU0683600562.USD","LU0823434740.USD","LU2168564065.EUR","LU1093756168.USD","LU2462591350.SGD","LU1366192091.USD","LU0225283273.USD","LU1023059063.AUD","BK4533","LU2271345857.HKD","LU2213496289.HKD","ELIS","IE00B775H168.HKD","LU2063271972.USD","LU1988902786.USD","LU1804176565.USD","LU0471298694.HKD","LU0174119429.USD","LU0787776722.HKD","LU0882574139.USD","CURE","IE00BN29S564.USD","LU0345770993.USD","LU0238689110.USD","LU1291159041.SGD","IE00B1BXHZ80.USD","LU1035775433.USD","LU2264538146.SGD","SG9999018857.SGD","LU0158827948.USD","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173269814","title":"Market Wrap September 10: Innovation Drug Shares Dip Amid Clinical Setback, Bank Stocks Post Modest Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1173269814","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173269814?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:55","pubTimestamp":1789030552,"startTime":"0","endTime":"0","summary":"Hong Kong equities extended their losing streak as escalating Middle East tensions and rising oil prices stoked inflation concerns. A combination of factors, including clinical trial risk events,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LNGR","VTV","159992","SWP","IBBQ","VUSV","BK4585","VMAX","BK1161","VALQ","ROPE","BK4550","EQRR","MEDX","PRF","BK1574","FDN","CGVV","PY","06978","ABEQ","BKDV","DFLV","VLUE","SPVM","TALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563044","title":"Medmix Teams with Xeris to Power Precise Delivery of New Hypothyroidism Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563044","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563044?lang=en_us&edition=fundamental","pubTime":"2026-09-10 15:32","pubTimestamp":1789025547,"startTime":"0","endTime":"0","summary":"An update from medmix AG ( ($CH:MEDX) ) is now available. Medmix’ Drug Delivery unit Haselmeier has entered a collaboration with Xeris Pharmaceutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medmix-teams-with-xeris-to-power-precise-delivery-of-new-hypothyroidism-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medmix-teams-with-xeris-to-power-precise-delivery-of-new-hypothyroidism-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666655750","title":"Novartis India Hits Record High After Recent Acquisition, Distribution Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2666655750","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666655750?lang=en_us&edition=fundamental","pubTime":"2026-09-10 13:29","pubTimestamp":1789018142,"startTime":"0","endTime":"0","summary":"BUZZ-Novartis India hits record high after recent acquisition, distribution deal** Pharma co Novartis India'sNOIN.BOshares rise 18% to 2,580 rupees, hitting an all-time high** Stock has gained in six of last seven trading sessions** Gains come after co on Tuesday said it entered into an exclusive promotion and distribution agreement with Novartis Healthcare to market its retina portfolio in India** On Monday, Novartis India said that it would acquire the Minipress brand and related IP from PfizerPFE.Nfor about 12.5 billion rupees ** NOIN holds trailing 12-month PE of 55.26 vs industry median of 23.98","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL4N4520C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU0306806265.USD","SG9999001176.USD","LU0225284248.USD","IE00B4R5TH58.HKD","SGXZ57979304.SGD","IE00BLSP4239.USD","LU0321505439.SGD","SG9999013999.USD","BK4007","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU1057294990.SGD","IE00BLSP4452.SGD","LU0320765489.SGD","OZEM","BK4550","BK4532","SG9999001176.SGD","LU0070302665.USD","LU0306807586.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU1023059063.AUD","LU0456855351.SGD","LU2596442595.SGD","SG9999003800.SGD","SG9999002232.USD","BK4578","IE0002270589.USD","LU1894683348.USD","LU0058720904.USD","LU1894683264.USD","MEDX","LU0868494617.USD","IE00BJJMRZ35.SGD","PFE","IE000M9KFDE8.USD","IE0002141913.USD","IE00B2B36J28.USD","NVS","BK4592","LU0321505868.SGD","LU1066053197.SGD","IE00BJT1NW94.SGD","PPH","SG9999011175.SGD","LU0234572021.USD","LU0170899867.USD","IE00B19Z3581.USD","IE0009355771.USD","BK4588","BK4599","LU0225771236.USD","BK4533","BK4581","LU1066051498.USD","LU1883839398.USD","BK4534","IE00B3T34201.USD","LU0208291251.USD","BK4568","LU0985481810.HKD","LU0122379950.USD","LU0211331839.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1199145560","title":"Tellgen's Subsidiary Device Registration Application Accepted by Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1199145560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199145560?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:54","pubTimestamp":1789012483,"startTime":"0","endTime":"0","summary":"Tellgen Corporation (SZSE: 300642) has announced that its controlling subsidiary, Shanghai Maishi Biotechnology Co., Ltd., recently had its medical device registration application accepted for review...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEIH","BK0239","MEDX","GDOC","MDEV","159883","HART","RSPH","BK0042","BK0046","09996","BK1574","300642","AGNG","BK1100","PTH","BK1583","LNGR","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192676541","title":"Northeast Securities: Innovative Drug BD and Commercialization Deliver Consistent Wins, CXO Exceeds Projections, Traditional Segments Approach Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=1192676541","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192676541?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:08","pubTimestamp":1789006103,"startTime":"0","endTime":"0","summary":"Investment banking firm Northeast Securities Co.,Ltd. has released a research report indicating that the high prosperity of the overseas innovative drug industry is set to continue, allowing domestic...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","IBBQ","BK0276","WX","CXO","BK0183","BK1574","BK0028","BK0188","BK1161","000686","MEDX","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103728541","title":"AI-Driven Drug Candidate From INSILICO Reaches Major Milestone As Phase 3 Trial Enrolls First Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1103728541","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103728541?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:26","pubTimestamp":1789000007,"startTime":"0","endTime":"0","summary":"INSILICO (03696) has announced that its lead artificial intelligence-powered investigational drug, Rentosertib (also known as ISM001-055/INS018_055), has achieved a significant clinical milestone...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBDS","WPAI","TQQQ","03455","BMED","OGIG","QQQ","QQQM","IBBJ","07261","07522","CWC","MFIG","AQGX","TECY","09834","QSWN","QMAR","BK1161","PSYK","TARK","BK4593","BK1574","KOMP","MEDX","09086","AGIX","IBBQ","AIQU","CPNQ","NEWZ","NOCT","06978","QID","161631","MVPS","CHAT","03696","LNGR","LCLG","PBOT","FWD","GK","AIBU","03034","QDEC","QLD","AIFD","GPIQ","PSQ","QQA","BK1141","TQQY","02834","03086","VUSE","DQJN","MDTX","QQQX","07266","07568","ARTY","NJUL","NAPR","SQQQ","159992","QTOC","NJAN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":10,"totalSize":306,"code":"91000000","status":"200"}]}}